Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis

Company Overview

Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing treatments for diseases of the eye. Its research programs address conditions affecting the retina and other ocular tissues, with an emphasis on therapies that may offer new treatment options for patients with limited or no approved alternatives.

The company’s pipeline has included KIO-301, an investigational small-molecule photoswitch designed to provide light sensitivity and potentially restore visual function in people with inherited retinal diseases such as retinitis pigmentosa. Kiora has also developed investigational ophthalmic therapies for inflammatory and surface-related eye disorders, including KIO-104 for noninfectious uveitis and KIO-101 for dry eye disease. These candidates remain subject to clinical and regulatory evaluation.

Kiora was formerly known as EyeGate Pharmaceuticals and adopted the Kiora Pharmaceuticals name as it expanded its focus on retinal and other ophthalmic diseases. The company is headquartered in the United States and has conducted clinical development activities in the United States and internationally, including Australia. Kiora Pharmaceuticals trades on the Nasdaq under the symbol KPRX.

Key Stats

• Today's Range: $2.45 to $2.49
• 50-Day Range: $2.47 to $2.76
• 52-Week Range: $1.76 to $2.91
• Volume: 15,673 shs
• Average Volume: 177,331 shs
• Market Capitalization: $10.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Kiora Pharmaceuticals Stock Analysis - MarketRank™

Kiora Pharmaceuticals scored higher than 25% of companies evaluated by MarketBeat, and ranked 792nd out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Kiora Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Kiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Kiora Pharmaceuticals is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Kiora Pharmaceuticals is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Kiora Pharmaceuticals has a P/B Ratio of 0.56. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.08% of the float of Kiora Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Kiora Pharmaceuticals has a short interest ratio ("days to cover") of 0.24, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Kiora Pharmaceuticals has recently decreased by 14.61%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Kiora Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Kiora Pharmaceuticals does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

Kiora Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Kiora Pharmaceuticals this week, compared to 1 article on an average week.

Search Interest

1 people have searched for KPRX on MarketBeat in the last 30 days.

MarketBeat Follows

1 people have added Kiora Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Kiora Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.52% of the stock of Kiora Pharmaceuticals is held by insiders.

Percentage Held by Institutions

76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/06/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:KPRX
• CIK: 1372514
• Web: www.kiorapharma.com
• Phone: (858) 224-9600
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$10.84 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -63.38%
• Return on Assets: -44.33%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 8.97
• Quick Ratio: 8.97

Sales & Book Value

• Annual Sales: $16.02 million
• Price / Sales: 0.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.38 per share
• Price / Book: 0.56

Miscellaneous

• Outstanding Shares: 4,420,000
• Free Float: 4,401,000
• Market Cap: $10.87 million
• Optionable: Not Optionable
• Beta: -0.22